Changing the course of autoimmune disease

Inspired by patients. Driven to make an impact.

Aurinia’s Response to COVID-19

View

Latest News

July 16, 2021 • 5:30pm EDT

Aurinia Pharmaceuticals Announces Delisting from the Toronto Stock Exchange

Read Press Release View All News

June 30, 2021 • 7:05am EDT

Aurinia Awards $250,000 in Grants to Support Patient Navigation Programs

Read Press Release View All News

June 25, 2021 • 5:14am EDT

Aurinia Announces Licensing Partner Otsuka Filed Initial Marketing Authorization Application (MAA) for Voclosporin with the European Medicines Agency (EMA)

Read Press Release View All News